Barco extends its offering of FDA 510(k) cleared imaging solutions with next generation NIO display system family
KORTRIJK, BELGIUM, 24 March 2005 – Barco has received FDA 510(k) clearance from the U.S. Food and Drug Administration for its next generation NIO diagnostic display system family. With this clearance, Barco adds a new line of diagnostic display systems to its broad offering of FDA 510(k) cleared solutions for review and analysis of medical images.
The second generation of Barco’s NIO display system was first showcased at last November’s RSNA conference, where it was immediately praised for its ultra-fast display controller, its extended softcopy Quality Assurance functionality and its attractive new design. Uniting performance and affordability, the innovative NIO line successfully addresses the needs of healthcare professionals for a high-quality, yet cost-effective solution for diagnostic viewing.Barco’s NIO line is available in 2 MegaPixel, 3 MegaPixel and 5 MegaPixel configurations. All of these are equipped with Barco’s proven Backlight Output Stabilization (BLOS) technology, which guarantees fast power-up and continuous DICOM conformance of the LCD’s luminance output. BLOS significantly improves the overall optical efficiency of NIO display systems and provides long-term diagnostic confidence.
NIO is a registered trademark of Barco.
About Barco
Barco, an international company headquartered in Kortrijk, Belgium, provides visualization and display solutions for professional markets. Barco designs and develops solutions for large screen visualization, display solutions for life-critical applications, and systems for visual inspection. Barco is active worldwide and has its own facilities for Sales & Marketing, Customer Support, R&D and Manufacturing in Europe, North America and Asia Pacific. Barco is quoted on Euronext Brussels and is a BEL 20 and a Next 150 company (Euronext: BAR; Reuters: BARBt.BR; Bloomberg: BAR BB).
